Skip to content 
Search

Latest Stories

There is 'no one-upmanship' in global Covid-19 vaccine race: Serum Institute CEO

IF the world is to gain access to a vaccine for Covid-19, there's a good chance it will pass through the doors of Serum Institute of India.

Serum Institute, the world's largest manufacturer of vaccines by volume, is working on several candidates for the novel coronavirus - including potentially mass-producing the AstraZeneca/Oxford University one that has garnered global headlines -- as well as developing its own.


The efforts are partly being shepherded by Umesh Shaligram, the head of research and development. His employer is a private company but every day, shortly before midnight, he receives a WhatsApp message from the government asking for updates, and about any new hurdles he faces.

The message is usually from K. VijayRaghavan, Prime Minister Narendra Modi's top scientific adviser -- an indication of the critical, and even strategically important, nature of the race to develop the vaccines the whole world is waiting for.

Shaligram promptly responds with a progress report and details any bottlenecks.

"Any delays, you just tell them," said Shaligram, adding the government has been doing everything it can to fast-track clearances, and resolve import delays and other issues.

"We have begun to see approvals come through in days, even on a Sunday night, for trials and things like that," he said, noting some of these processes typically took four to six months.

While most of the attention regarding vaccines typically goes to the pharmaceutical developer, India quietly plays a key role in manufacturing 60-70 per cent of all vaccines sold globally with the Serum Institute playing a lead role, said the company's Chief Executive Adar Poonawalla.

At the company's sprawling, 150-acre campus in the western Indian city of Pune, Shaligram and his team are working flat-out. Dozens of buses ferry in hundreds of workers each day to the grounds, which are buzzing with activity even as the city around it remains largely under lockdown.

The push comes as the number of cases of Covid-19, both globally and domestically, continue to surge and world leaders look to vaccines as the only real way to restart their stalled economies, even though none have yet been proven to be effective against the coronavirus.

Poonawalla, whose family owns he vaccine maker, said scientists, drugmakers and manufacturers were collaborating at an unparalleled scale to spur development and availability.

"We are all in a race to battle the disease, there is no one-upmanship here," he said sitting in his office beside his family's 74-year-old stud farm.

Serum, founded in 1966 by Adar's father Cyrus Poonawalla, has partnered with U.S. biotech firm Codagenix, its US rival Novavax and Austria's Themis to potentially manufacture three Covid-19 vaccine candidates that are still in development.

Another candidate in the works is the experimental vaccine developed by a team at the University of Oxford and now licensed to drugmaker AstraZeneca, with whom Serum are in talks to mass produce the vaccine, which is now in the clinical trial stage.

The US has secured almost a third of the first one billion doses planned for the potential vaccine, initially known as ChAdOx1 and now as AZD1222, by pledging up to $1.2 billion.

Poonawalla aims to initially produce four to five million doses a month, beginning from June, and then gradually ramp up to 350-400 million doses a year.

"Hopefully we will build a stock of a few million doses to give to our country and other high-risk areas across the globe come October-November when the trials ought to be concluded," the 39-year-old said.

He added he had been given to understand by the development team that the trials had an 80 per cent chance of success, given that the vaccine is based on a tried-and-tested platform.

Based on the information currently available, Poonawalla also said he anticipated AZD1222 would be a single-dose vaccine and not require a booster dose.

He sees AZD1222 potentially priced at about Rs 1,000 (£11) per dose in India, but expects it will be procured and distributed by governments without charge.

Serum is also working on developing its own in-house vaccine options to tackle the disease, Poonawalla said.

Even if a vaccine does succeed, a treatment to fight Covid-19 would still be required, said Poonawalla, noting some people do not get the desired immune response, even if vaccinated.

"You may get mild symptoms, you may get severe symptoms. It depends on your system, but there is a chance," he added. "Not all vaccines are fully effective."

The Serum Institute produces more than 1.5 billion doses of vaccines every year, for everything from polio to measles.

Poonawalla says that gave the company an edge in securing supplies of vials and high-quality chemicals required to make a vaccine in bulk once all approvals are in place.

"We have partnered with many of our suppliers to have one to two-year inventories of glass vials and tubing glass stocked in advance, so luckily for us that won't be an issue."

Any successful vaccine is however bound to be in short supply at first, he stressed.

India recorded more than 6,000 new cases of the coronavirus on Friday, bringing its total to over 118,000 cases with more than 3,500 deaths, even as it gradually begins to ease its nearly two-month long nationwide lockdown.

There have been more than five million infections and over 330,000 deaths reported worldwide.

The Indian government stands ready to cover the costs of trials of any vaccine in the country, said Poonawalla, adding that the government had also expressed interest in placing advance orders for a potential vaccine.

"We've reached out and they have been very positive," he added. "But we've said hold on ... as we don't want to take government money until we are very confident we can deliver."

UNLOCKING VALUE IN THE 'HYPE'

Serum, one of the few companies ramping up hiring during the health crisis, is also designing a separate facility to make vaccines for pandemic-level diseases that could handle 90 per cent of the current vaccine candidates being developed, beyond just the Covid-19 ones.

That facility, which will be ready in the next two to three years, would be able to potentially churn out 700-800 million doses a year, according to Poonawalla.

The CEO said he considered taking the company public some years ago to fund some large acquisitions, but changed course when the deals fell through.

Now he's considering a different approach. He is exploring creating a holding entity that will host the company's pandemic-level technologies, including manufacturing rights, intellectual property and the sale of all of Serum's Covid-19-related candidates, and selling a minority stake in the venture.

"That will unlock value in the main hype," he said.

Poonawalla said he had engaged bankers to test the waters on this, but stressed he would only consider selling a stake to ethical, long-term funds or sovereign funds that do not expect huge returns and want to "make a difference to the world".

"After getting them onboard, I don't want to be in a situation where I have to charge high prices to give them returns."

More For You

Ping Pong restaurant chain shuts all UK branches

The chain had also gained a following for its themed brunches

iStock

Ping Pong restaurant chain shuts all UK branches after 20 years

Key points

  • Chinese dim sum restaurant Ping Pong has closed all its UK locations
  • The chain made the announcement via social media
  • Founded in 2005, the brand thanked customers and staff for their support
  • Loyal diners shared memories and disappointment in the comments

All branches are permanently closed

Chinese restaurant chain Ping Pong has permanently closed all its branches in the UK, the company confirmed in a social media announcement.

Founded in 2005 by restaurateur Kurt Zdesar, the dim sum chain had become popular for its stylish interiors, creative menus, and Asian-inspired cocktails. The company did not provide prior notice of the closure but said the decision marked the end of an “unforgettable” 20-year journey.

Keep ReadingShow less
New Covid strain

Experts have raised concerns about the immune-evasive nature of the Stratus strain

iStock

New Covid strain Stratus spreads in UK with unusual hoarse voice symptom

Key points

  • A new Covid strain known as Stratus is spreading across the UK
  • The variant is marked by a distinctive symptom: a hoarse or raspy voice
  • Sub-variants XFG and XFG.3 now account for 30% of cases in England
  • Experts say there is no evidence of more severe disease
  • Lower immunity levels may make more people vulnerable to infection

Covid variant Stratus on the rise in the UK

A new strain of Covid-19, known as Stratus, is spreading across the UK and drawing attention for its unusual symptom — a hoarse or raspy voice. According to data from the UK Health Security Agency (UKHSA), Stratus and its two sub-variants, XFG and XFG.3, are responsible for around 30 per cent of Covid cases in England.

Of the two, XFG.3 is currently the more dominant. The UKHSA confirmed that monitoring of all circulating Covid-19 variants is ongoing as part of regular surveillance.

Keep ReadingShow less
Human brain continues forming neurons

Neurogenesis, the process by which new neurons form in the brain

iStock

Human brain continues forming neurons well into old age, study finds

Key points

  • New neurons continue forming in the brain’s hippocampus into old age
  • Study confirms presence of neural progenitor cells in adults
  • DNA carbon dating and single-nucleus RNA sequencing were used
  • Research shows variation in neuron production between individuals
  • Findings could aid treatments for neurodegenerative and psychiatric disorders

Human brain shows ongoing neuron formation into older age

A new study has confirmed that the human brain continues to produce new nerve cells well into late adulthood, challenging previous assumptions about age-related decline in neurogenesis. The findings, published in the journal Science, provide fresh insight into how adaptable the brain remains over a lifetime.

Neurogenesis, the process by which new neurons form in the brain, is known to occur in the hippocampus — a region involved in memory. While previous research has suggested that this process continues throughout life, there has been limited concrete evidence of the presence of neural progenitor cells in the adult brain.

Keep ReadingShow less
Kent County Show 2025

Sophie, Duchess of Edinburgh, who grew up in Brenchley

Getty Images

Kent County Show opens with royal visit from Duchess of Edinburgh

Key points:

  • Day one of the Kent County Show begins at Detling Showground near Maidstone
  • The Duchess of Edinburgh visits the event for the first time in 16 years
  • Organisers expect up to 70,000 visitors over the weekend
  • Farming and rural life are at the centre of the three-day programme
  • Highlights include live camel racing, equine sports, livestock displays and more

Kent County Show opens with royal visit

The Kent County Show returned to Detling near Maidstone on Friday, marking the start of a major three-day celebration of farming, food, and rural living. The event opened with a special visit from the Duchess of Edinburgh, who is attending for the first time in 16 years.

Sophie, Duchess of Edinburgh, who grew up in Brenchley near Tunbridge Wells and serves as patron of the Association of Show and Agricultural Organisations (ASAO), met with farmers, equine exhibitors, and local businesses on her tour of the showground.

Keep ReadingShow less
Sri Aurobindo

Heehs’s biography is grounded in extensive archival research across France, England, India and Israel

AMG

Sri Aurobindo and the rise of the Asian century

Dinesh Sharma

My friend and colleague, the American historian Peter Heehs, who has lived in Pondicherry, India, for decades, recently published a compelling new biography, The Mother: A Life of Sri Aurobindo’s Collaborator (2025). Heehs previously authored The Lives of Sri Aurobindo (2008), which remains one of the most balanced and scholarly accounts of Aurobindo’s life.

According to Heehs, most previous biographies of the Mother were written for devotees and relied on secondary sources, often presenting her as a divine incarnation without critical engagement. “Such biographies are fine for those who see the Mother as a divine being,” Heehs said, “but they can be off-putting for readers who simply want to understand her life – as an artist, writer, spiritual teacher, and founder of the Ashram and Auroville.”

Keep ReadingShow less